LEVERAGE SHARES PUBLIC LIMITED
ARGS.L
London Stock Exchange1.57
USD
-0.05
(-3.25%)
Return %
Stock
S&P500
1Y
-50.26
26.53
3Y
-68.59
76.60
5Y
-68.59
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- IPO Date
- Dec 10, 2021
- Similar Companies
- Business
- Leverage Shares -3x Short ARK Genomic Revolution ETF (ARGS.L) is an exchange-traded fund (ETF) that provides leveraged inverse exposure to the performance of the ARK Genomic Revolution ETF, seeking daily investment results of -3 times the daily performance of its underlying index before fees and expenses. The fund employs swap agreements, futures contracts, options, and other financial derivatives to achieve its leveraged short objectives; it does not invest directly in the securities of the ARK Genomic Revolution ETF but replicates inverse exposure through these instruments. Primarily targeting sophisticated investors and institutions seeking to hedge or speculate on downturns in genomic innovation sectors, including biotechnology, genomics, and health tech, the ETF trades on the London Stock Exchange with a focus on European and global markets. Operated by Leverage Shares Management Company, headquartered in London, United Kingdom, and established in recent years as part of the firm's expansion into single-stock and thematic leveraged ETPs, the fund fits within the broader alternative investment segment of leveraged and inverse ETFs. No major recent partnerships, funding rounds, acquisitions, new product launches, or strategic shifts specific to ARGS.L have been publicly reported in the last 1-2 years; the issuer continues standard operations amid ongoing regulatory oversight by the Financial Conduct Authority (FCA). Leverage Shares offers a suite of similar -3x short and long ETPs across technology, finance, and sector themes, with ARGS.L serving niche demand in the volatile genomics space.